Mirum Pharmaceuticals stock
MIRMNASDAQMirum Pharmaceuticals, Inc., HealthcareISIN US6047491013
38Score 38 out of 100, Weak
Price and trend
56 / 100
Price history
+32% in one yearThe chart shows daily closes over 7 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 5.2% below it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Overheated: the price has risen very quickly lately (RSI 75).
The price is 27% below its 52-week high. Largest decline in 7 years: 64% (December 2019 to March 2020).
Chart figures for advanced users
- SMA 50$88.92
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$98.45
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)75
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$64.10
- The lowest closing price of the last twelve months.
- Resistance$128.57
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Mirum Pharmaceuticals, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $6.09B, is number 66 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $521.31M (up 54.7% year on year) and a loss of $23.36M.
- For fiscal 2026, analysts expect on average revenue of $715.85M (up 37.3%) and adjusted earnings per share of −$15.18.
Show more
- MEQIRI Score 38 out of 100 (Weak): rank 564 of 702 in Healthcare, median 53.
- Our model puts fair value at $37.34, with the price 150% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- DilutionShare count up 99% since 2020.Capital allocation 18
- Above fair valuePrice 150% above the fair value of $37.34.Valuation 17
- Loss-makingLoss of $903.88M over the last 12 months.Fundamentals 17
The score is held back by fundamentals and valuation.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $26.67 and expensive above $62.24 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 9.7%. At 10.7% the fair value would be $31.45, at 8.7% it would be $45.69.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 42.2% on the twelve months before. Revenue turned from negative at the start of the period to positive ($521.31M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 81%, operating −4%, net −4%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 24 Feb 2027in 103 days
- Last reported
- 3 Nov 2026EPS reported −$0.87 (expected −$0.49)below expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 78.3% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$15.18−0.4%
- Revenue
- $715.85M+2.6%
- Earnings per share
- −$1.25−78.3%
- Revenue
- $869.66M+6.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −9.8%2026 net product sales guidance raised to $680 to $700 million on strong demand.
“Based on this performance, we are increasing our full year 2026 net product sales guidance to $680 million to $700 million Fueled by the strong commercial performance, we are driving towards the next phase of Mirum's growth with multiple milestones over the coming months.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 4 insiders sold, $20.18M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Peetz ChristopherSale
4 Nov 2026, CHIEF EXECUTIVE OFFICER
- Shares
- 20,000
- Price
- $90.00
- Value
- $1.8M
- Bjerkholt EricSale
14 Sept 2026, CHIEF FINANCIAL OFFICER
- Shares
- 9,943
- Price
- $98.37
- Value
- $978,093
- Howe JolandaSale
2 Sept 2026, SVP, GLOBAL CONTROLLER
- Shares
- 658
- Price
- $100.00
- Value
- $65,800
Show 13 more
- Peetz ChristopherSale
1 Sept 2026, CHIEF EXECUTIVE OFFICER
- Shares
- 30,000
- Price
- $98.68
- Value
- $2.96M
- Howe JolandaSale
18 Aug 2026, SVP, GLOBAL CONTROLLER
- Shares
- 40,000
- Price
- $100.00
- Value
- $4M
- Bjerkholt EricSale
11 Aug 2026, CHIEF FINANCIAL OFFICER
- Shares
- 6,001
- Price
- $99.90
- Value
- $599,510
- Peetz ChristopherSale
10 Aug 2026, CHIEF EXECUTIVE OFFICER
- Shares
- 20,000
- Price
- $98.92
- Value
- $1.98M
- Howe JolandaSale
3 Aug 2026, SVP, GLOBAL CONTROLLER
- Shares
- 1,840
- Price
- $105.29
- Value
- $193,734
- Peetz ChristopherSale
6 Jul 2026, CHIEF EXECUTIVE OFFICER
- Shares
- 20,000
- Price
- $122.27
- Value
- $2.45M
- Bjerkholt EricSale
6 Jul 2026, CHIEF FINANCIAL OFFICER
- Shares
- 5,000
- Price
- $122.25
- Value
- $611,273
- Howe JolandaSale
1 Jul 2026, SVP, GLOBAL CONTROLLER
- Shares
- 2,721
- Price
- $120.00
- Value
- $326,520
- Howe JolandaSale
17 Jun 2026, SVP, GLOBAL CONTROLLER
- Shares
- 2,594
- Price
- $101.95
- Value
- $264,458
- Bjerkholt EricSale
8 Jun 2026, CHIEF FINANCIAL OFFICER
- Shares
- 5,000
- Price
- $93.82
- Value
- $469,077
- Peetz ChristopherSale
1 Jun 2026, CHIEF EXECUTIVE OFFICER
- Shares
- 30,000
- Price
- $95.84
- Value
- $2.88M
- Ramasastry SairaSale
1 Jun 2026, Board
- Shares
- 3,977
- Price
- $100.00
- Value
- $397,700
- Ramasastry SairaSale
15 May 2026, Board
- Shares
- 2,000
- Price
- $109.47
- Value
- $218,940
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Mirum Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 38
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Samsung Epis Holdings0126Z0.KS $6.4B41
- Ligand PharmaceuticalsLGND $6.33B60
- CG OncologyCGON $6.27B41
- Hangzhou Tigermed Consulting300347.SZ $6.12B46
- Scholar Rock HoldingSRRK $5.71B35
- Anthem BiosciencesANTHEM.NS $5.62B78
- Shanghai Allist Pharmaceuticals688578.SS $5.61B66
- ErascaERAS $5.52B44
ETFs that hold Mirum Pharmaceuticals
Held by 14 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Pharma Breakthrough UCITS ETFETLI | 2.38% | 0.49% | €26.29M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.40% | 0.35% | €1.25B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.20% | 0.30% | €185.82M |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.15% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.15% | 0.30% | €2.22B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.04% | 0.43% | €2.5B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.04% | 0.35% | €8.27B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.02% | 0.10% | €395.74M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jul 2020)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.